# Debate Matchup Judgment Report

**Claude Opus 4.7 (high)** vs **Baidu Ernie 5.1**

- Paired result: **Claude Opus 4.7 (high)**
- Mean entertainment: `8.00 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Public health systems should fund mitochondrial replacement therapy to prevent severe inherited mitochondrial disease.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0665__claude-opus-4-7-adaptive__ernie-5.1__s0__tpl_placement_active_20260320f.md): PRO = **Claude Opus 4.7 (high)**, CON = **Baidu Ernie 5.1**
- [Debate B transcript](../../../transcripts/prop_0665__ernie-5.1__claude-opus-4-7-adaptive__s1__tpl_placement_active_20260320f.md): PRO = **Baidu Ernie 5.1**, CON = **Claude Opus 4.7 (high)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_glm53_coverage_20260904a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0665__claude-opus-4-7-adaptive__ernie-5.1__s0__tpl_placement_active_20260320f.md)
- Roles: PRO = **Claude Opus 4.7 (high)**, CON = **Baidu Ernie 5.1**
- Judged result: Unanimous `3-0` for **Claude Opus 4.7 (high)**.
- Entertainment scores: `8`, `8`, `8`
- Mean signed raw margin (PRO+): `+2.20`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| GPT-5.5 (high) | A = Claude Opus 4.7 (high) (PRO); B = Baidu Ernie 5.1 (CON) | Claude Opus 4.7 (high) | +1.8 | +1.93 | 8.0 |
| Gemini 3.1 Pro Preview | A = Baidu Ernie 5.1 (CON); B = Claude Opus 4.7 (high) (PRO) | Claude Opus 4.7 (high) | +2.8 | +2.33 | 8.0 |
| Qwen 3.6 Max Preview | A = Claude Opus 4.7 (high) (PRO); B = Baidu Ernie 5.1 (CON) | Claude Opus 4.7 (high) | +2.0 | +2.00 | 8.0 |

### Judge Notes

- **GPT-5.5 (high)** (A = Claude Opus 4.7 (high) (PRO); B = Baidu Ernie 5.1 (CON)): Side A won by making the counterfactual clearer: public funding versus no meaningful access for families facing severe disease. Side B had a serious safety route on germline uncertainty and a plausible opportunity-cost concern, but its equity argument was badly damaged when it conceded private markets would not deliver access. A also gave more persuasive answers on specialist referral systems and regulated staged use, while B relied on repeated caution without fully explaining why that threshold should override the immediate prevention of catastrophic disease.
  Most decisive rebuttal noted: Side A’s pressure on private provision was decisive: B admitted no private reproductive technology had solved access for low-income carriers, which let A crystallize the debate as public funding versus no access rather than public versus private delivery.
- **Gemini 3.1 Pro Preview** (A = Baidu Ernie 5.1 (CON); B = Claude Opus 4.7 (high) (PRO)): Side B wins decisively because Side A commits a fatal strategic error under pressure. After arguing in earlier speeches that private provision would expand capacity and access, Side A explicitly concedes in Rebuttal 2 that private markets will not deliver MRT to low-income families, completely validating Side B's equity argument for public funding. Side B also effectively parried the safety and cost arguments with strong analogies (tertiary referral networks, existing ultra-rare disease funding).
  Most decisive rebuttal noted: Side B's Rebuttal 2 answer on how a low-income patient gets treated (referencing existing tertiary referral pathways like proton beam therapy) cleanly dismantled Side A's geographic equity argument.
- **Qwen 3.6 Max Preview** (A = Claude Opus 4.7 (high) (PRO); B = Baidu Ernie 5.1 (CON)): Side A wins decisively by forcing a major concession on equity and maintaining a tighter, more compelling comparative frame. Side B's opening relied on private markets eventually improving access, but in Rebuttal 2, B explicitly conceded that private provision would not solve inequity for this niche technology. Side A immediately capitalized on this in the closing, correctly framing the choice as public funding versus no access. Side A also handled the germline safety pressure more effectively by distinguishing mitochondrial DNA from nuclear identity and grounding the risk assessment in existing regulatory pathways and the devastating counterfactual of Leigh syndrome. Side B's precautionary stance was coherent but became isolated and less persuasive after the equity collapse, and A's rhetorical framing of the stakes was consistently sharper.
  Most decisive rebuttal noted: Side A's Rebuttal 2 and Closing, which forced and exploited Side B's explicit concession that private markets would not deliver equitable access, effectively collapsing one of CON's three opening pillars and reframing the entire debate around a binary choice between public prevention and preventable death.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0665__ernie-5.1__claude-opus-4-7-adaptive__s1__tpl_placement_active_20260320f.md)
- Roles: PRO = **Baidu Ernie 5.1**, CON = **Claude Opus 4.7 (high)**
- Judged result: Unanimous `3-0` for **Claude Opus 4.7 (high)**.
- Entertainment scores: `8`, `8`, `8`
- Mean signed raw margin (PRO+): `-2.30`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| GPT-5.5 (high) | A = Baidu Ernie 5.1 (PRO); B = Claude Opus 4.7 (high) (CON) | Claude Opus 4.7 (high) | -2.4 | -2.57 | 8.0 |
| Gemini 3.1 Pro Preview | A = Claude Opus 4.7 (high) (CON); B = Baidu Ernie 5.1 (PRO) | Claude Opus 4.7 (high) | -2.5 | -2.08 | 8.0 |
| Qwen 3.6 Max Preview | A = Baidu Ernie 5.1 (PRO); B = Claude Opus 4.7 (high) (CON) | Claude Opus 4.7 (high) | -2.0 | -2.00 | 8.0 |

### Judge Notes

- **GPT-5.5 (high)** (A = Baidu Ernie 5.1 (PRO); B = Claude Opus 4.7 (high) (CON)): B won by making the honest comparator decisive: MRT should be compared to PGD, donor eggs, and adoption, not to untreated severe disease. A’s case depended on broad cost savings and safety claims that were overprecise and weakly grounded, especially the late defended “over 100 births” claim and the flawed handling of egg donation. B also weighed opportunity cost and germline uncertainty more clearly, while A never fully justified why public systems must fund genetic relatedness for a small subgroup.
  Most decisive rebuttal noted: B’s first rebuttal on the substitution error was decisive: it reframed A’s cost-saving case away from “MRT versus untreated disease” and toward “MRT versus existing cheaper alternatives,” sharply shrinking A’s benefit claim.
- **Gemini 3.1 Pro Preview** (A = Claude Opus 4.7 (high) (CON); B = Baidu Ernie 5.1 (PRO)): Side A won decisively by exposing a fundamental 'substitution error' in Side B's cost-benefit analysis: MRT does not save millions compared to the real alternatives (PGD or egg donation), it only saves millions compared to untreated disease. Side B struggled to defend why the state should fund genetic relatedness over cheaper, safer alternatives, and made a biological error in Rebuttal 2 when trying to critique egg donation.
  Most decisive rebuttal noted: Side A's Rebuttal 2 answer to PQ2 was philosophically sharp: vaccines protect a future person on their only path into existence, whereas MRT selects which person comes into existence, making it a reproductive preference rather than standard disease prevention.
- **Qwen 3.6 Max Preview** (A = Baidu Ernie 5.1 (PRO); B = Claude Opus 4.7 (high) (CON)): Side B wins by decisively controlling the core comparative frame. Side A built a compelling prevention and cost-saving case, but it relied on comparing MRT to untreated disease. Side B successfully dismantled this by establishing PGD, egg donation, and adoption as the real, cheaper counterfactuals that public systems already use. B consistently pressed A to quantify the narrow subgroup that actually needs MRT, shifting the burden of proof and collapsing A's economic landslide into a marginal claim. B also demonstrated superior epistemic discipline, correctly challenging A's brittle precision on UK birth numbers and follow-up horizons, while framing the germline safety risk and opportunity cost in terms public health systems actually prioritize. A's responses were structured and competent but never fully resolved the comparator problem or defended the size and necessity of the target subgroup against B's sustained pressure.
  Most decisive rebuttal noted: Side B's identification and exploitation of the "substitution error" across Rebuttals 1 and 2. B sharply recognized that A's entire economic and moral case depended on comparing MRT to untreated Leigh syndrome rather than to existing alternatives like PGD or donor eggs. By forcing the debate onto the marginal benefit for a small, unquantified subgroup and distinguishing MRT's embryo selection from standard disease prevention, B materially dismantled A's path to victory and controlled the weighing for the remainder of the debate.

## Technical metadata

- Evaluation scope: `judge_judge_blend_glm53_coverage_20260904a__debate_all_templates`
- Topic ID: `prop_0665`
- Side-swap group ID: `prop_0665__claude-opus-4-7-adaptive__ernie-5.1__tpl_placement_active_20260320f`
- Raw paired winner: **Claude Opus 4.7 (high)**
- Mean normalized margin for Claude Opus 4.7 (high): `+2.15`
- Complete side swap: `yes`
- Included in ratings: `yes`
